Highlights Novartis AG

Equities

NOVN

CH0012005267

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 10:59:51 2025-12-05 EST			5-day change	1st Jan Change
107.03 ^CHF	+0.14%		+2.39%	+20.61%

11:40pm	Lupin Gets Tentative U.S. FDA Nod for Siponimod Tablets	MT
12-03	Sector Update: Health Care Stocks Higher Late Afternoon	MT

Highlights

Lupin Gets Tentative U.S. FDA Nod for Siponimod Tablets	11:40pm	MT
Mizuho's Katz sees 'fertile' conditions driving robust M&A market into 2026	12-03	RE
Tiziana Life Sciences Plans to Spin Out Asset as Separate Company	12-02	DJ
US FDA approves Otsuka's drug for a type of kidney disease	11-25	RE
Swiss Market Index Closes Higher; Emmi, Novartis Shares Up	11-25	MT
Global markets live: Amazon, Alphabet, Boeing, Novartis, Novo Nordisk…	11-25
Sector Update: Health Care Stocks Edge Higher Premarket Tuesday	11-25	MT
Exchange-Traded Funds Higher, Equity Futures Lower Pre-Bell Tuesday Ahead of Delayed Data Releases	11-25	MT
Novartis Gets FDA Approval for Spinal Muscular Atrophy Treatment; Shares Rise Premarket	11-25	MT
Novartis to present phase III trial for ianalumab in ITP	11-25	RE
Novartis' Spinal Muscular Atrophy Treatment Wins US FDA Approval	11-24	MT
Novartis prices Itvisma at a wholesale acquisition cost of $2.59 million	11-24	RE
US FDA approves Novartis' gene therapy for rare muscle disorder	11-24	RE
Novartis receives FDA approval for Itvisma	11-24	RE
Novartis Receives FDA Approval for Itvisma®?, the Only Gene Replacement Therapy for Children Two Years and Older, Teens, and Adults with Spinal Muscular Dystrophy	11-24	CI
DKSH Management Ltd. Announces Executive Changes	11-21	CI
Global markets live: Nvidia, Walmart, Google, Amgen, Target…	11-20
Sector Update: Health Care Stocks Edge Higher Premarket Thursday	11-20	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Jobs Data	11-20	MT
Novartis Maintains Growth Targets, Lifts Peak Sales Outlook for Kisqali, Scemblix	11-20	MT
Novartis Expects Key Drugs, Recent Deals to Buoy Sales Into 2030s -- Update	11-20	DJ
Novartis Rolls Forward Mid-Term Sales Outlook to 2025-2030, Expects Over 5% to 6% Sales CAGR	11-20	MT
European shares advance on Nvidia results lift; investors assess US jobs data	11-20	RE
Novartis Expects Steady Sales Growth Through 2030	11-20	DJ
Novartis Targets Up to 6% Annual Growth in Sales Through FY30	11-20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

NOVARTIS : Q3 largely met expectations; wait for sentiment-driven dips

October 28, 2025 at 11:00 am

Novartis CEO Says They Will Have to 'Tackle Rhetoric' in US Healthcare

January 21, 2025 at 05:56 am